Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis

作者：Diana Zhang, Shayesteh Jahanfar, Judy Rabinowitz, Joshua Dower, Fei Song, Cherng-Horng Wu, Xiao Hu, Phillip Tracy, Mark Basik, Arielle J. Medford, Po-Han Lin, Chiun‐Sheng Huang, François‐Clément Bidard, Shufang Renault, Lori Pai, Mary K. Buss, Heather A. Parsons, Ilana Schlam · 发表于：Breast Cancer Research · 年份：2025 · DOI：10.1186/s13058-025-01986-y · 被引用次数：22 · 研究领域：Cancer Genomics and Diagnostics、Cancer Cells and Metastasis、Breast Cancer Treatment Studies

BACKGROUND: Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers and carries a worse prognosis relative to other breast cancer subtypes. This systematic review and meta-analysis evaluated the prognostic value of circulating tumor DNA (ctDNA) in early-stage TNBC. METHODS: A literature search was conducted using Ovid Medline, Elsevier EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science Databases for publications up to 11/16/2023. Results were uploaded to Covidence and assessed by two independent reviewers. Studies assessing the use of ctDNA to predict recurrence free survival and related outcomes as well as overall survival were included. All recurrence outcomes were combined during analysis. Statistical analysis was performed using Revman Web. Log-hazard ratios (HR) were pooled for studies reporting recurrence and death as a time-to-event outcomes. Odds ratios (OR) were calculated and pooled for studies reporting patient-level data on recurrence, death, and pathological complete response (pCR). Prospero ID: CRD42023492529. RESULTS: A total of 3,526 publications were identified through our literature search, and 20 publications (n = 1202 patients) were included in the meta-analysis. In studies that reported recurrence as a time-to-event outcome, post-neoadjuvant (before or after surgery) ctDNA + status was associated with a higher likelihood of disease recurrence (HR 4.12, 95% confidence interval [CI] 2.81-6.04). For studies that re...